诺和诺德Novo Nordisk (NVO) 2013年年度报告「NYSE」.pdf

1、 novo nordisk annual report 2013If Novo Nordisksbusiness strategywere to be describedin one word,it would haveto be focusThe one rule wehave to break the Rule of HalvesOne sizedoesnt fi t all when it comes todiabetes treatmentIs obesitya disease?without doubt itis a growing threatto global healthCon

2、tentsThe Management review,as defined by the Danish Financial Statements Act(FSA),is found on pp 154 and 94.This Annual Report is published in both a Danish and an English version.In the event of any discrepancies,the Danish version shall prevail.Our business 16 Business strategy:Our focus is our st

3、rength 20 Pipeline overview 22 The one rule we have to break 24 One size doesnt fit all 26 Changing diabetes where it matters most 28 Is obesity a disease?30 An important factor of life 31 Novo Nordisks five regions 36 The complexity of insulin production 38 A question of trust 42 Risks to be aware

4、ofGovernance,leadership and shares 44 Shares and capital structure 46 Corporate governance 49 Remuneration 52 Board of Directors 54 Executive ManagementFinancial,social and environmental statements 55 Consolidated financial,social and environmental statements104 Financial statements of the parent co

5、mpany109 Managements statement and Auditors reportsAdditional information112 More information113 Product overviewAccomplishments and results 2013 1 Letter from the Chairman 2 Letter from the CEO 4 Novo Nordisk at a glance 6 2013 performance and 2014 outlook 14 Performance highlights244222The one rul

6、e we have to breakOne size doesnt fit all4Business strategy:Our focus is our strengthNovo Nordisks five regionsRisks to be aware of163162013 performance and 2014 outlookChairman of the Board of Directors Gran Ando at the Novo Nordisk R&D Summit in November 2013.Letter from the ChairmanLast year,at N